Back

Cardiovascular effects associated with androgen deprivation therapy: current mechanistic understanding, clinical relevance, and limitations

19 June 2026 (15:40 - 15:55)
Organised by: Logo
Congress Presentation Part of: Androgen deprivation therapy in prostate cancer and cardiovascular risk: mechanistic and clinical considerations Cardiovascular Toxicity of Cancer Therapies Open Access ESC Cardio-Oncology 2026 Council of Cardio-Oncology

About the speaker

Photo
Doctor Belen Terol

Quiron University Hospital, Madrid (Spain)

3 More presentations in this session

Presentation thumbnail
Introduction: epidemiological data and current evidence of androgen deprivation therapy associated cardiovascular effects
Professor S. Szmit (Warsaw, PL)
Presentation thumbnail
Differential effects of androgen deprivation therapy modalities on platelet phenotype: results from an exploratory clinical study
Doctor A. Beitzen Heineke (Hamburg, DE)
Presentation thumbnail
Conclusion

Access the full session

Session thumbnail
Androgen deprivation therapy in prostate cancer and cardiovascular risk: mechanistic and clinical considerations

The Event

Event poster

ESC Cardio-Oncology 2026

19 June 2026 15:40 CET
You may be interested in
thumbnail
Congress Presentation
Androgen deprivation therapy with agonists of GnRH: cardiovascular adverse events and comorbidity considerations in patients with prostate cancer
27 August 2021
thumbnail
Webinar
How to manage cancer therapy-related cardiovascular toxicity. ESC 2022 Clinical Practice Guidelines - Webinar Series
19 September 2022
thumbnail
Congress Presentation
Left ventricular thrombus and multiple emboli in a young bodybuilder
27 August 2023
thumbnail
ESC TV Today
Episode 26: Lp(a): the future starts now - Myocardial infarction in older age and frailty
6 November 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources